{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:27:24Z","timestamp":1793618844862,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ebiom.2026.106529","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:25:06Z","timestamp":1792509906000},"page":"106529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetically informed therapy for valvular heart disease: what, where, and when to target"],"prefix":"10.1016","volume":"133","author":[{"given":"Yuze","family":"Mi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4507-0093","authenticated-orcid":false,"given":"Yanggang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebiom.2026.106529_bib1","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1161\/CIR.0000000000001254","article-title":"Unraveling the mechanisms of valvular heart disease to identify medical therapy targets: a scientific statement from the American Heart Association","volume":"150","author":"Small","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2026.106529_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106499","article-title":"Mapping human genetic associations to drug targets in valvular heart disease: an integrative evidence synthesis","author":"Moura-Ferreira","year":"2026","journal-title":"eBioMedicine"},{"issue":"8012","key":"10.1016\/j.ebiom.2026.106529_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106529_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41576-025-00904-4","article-title":"Genomics of drug target prioritization for complex diseases","volume":"27","author":"Chen","year":"2026","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106529_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41588-025-02417-6","article-title":"Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction","volume":"58","author":"Small","year":"2026","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106529_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41588-025-02397-7","article-title":"Multitrait analyses identify genetic variants associated with aortic valve function and aortic stenosis risk","volume":"58","author":"Kany","year":"2026","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106529_bib7","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ebiom.2026.106529_bib8","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.121.053708","article-title":"Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial","volume":"143","author":"Pawade","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106529_bib9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106529_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.123.066523","article-title":"Reactivation of oxidized soluble guanylate cyclase as a novel treatment strategy to slow progression of calcific aortic valve stenosis: preclinical and randomized clinical trials to assess safety and efficacy","volume":"151","author":"Zhang","year":"2025","journal-title":"Circulation"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426004135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426004135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:51:57Z","timestamp":1793616717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426004135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"alternative-id":["S2352396426004135"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106529","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically informed therapy for valvular heart disease: what, where, and when to target","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106499","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106529"}}